The efficacy of exenatide and liraglutide among South Asians in the Association of British Clinical Diabetologists nationwide audits

KY Thong¹, P Sen Gupta^1,2, REJ Ryder¹

¹Department of Diabetes, City Hospital, Birmingham, UK
²Diabetes Research Group, King’s College, London, UK

Switching exenatide or gliptins to liraglutide in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit

K.Y. Thong¹, K. Darzy², M.L. Cull¹, A.P. Mills¹, R.E.J. Ryder¹, ABCD nationwide exenatide and liraglutide audit contributors;

¹City Hospital, Diabetes, Birmingham, UK

²Queen Elizabeth II Hospital, Diabetes, Welwyn Garden City, UK

Factors associated with HbA1c and weight changes in the Association of British Clinical Diabetologists (ABCD) nationwide GLP-1 agonists audit

K.Y. Thong¹, R.E.J. Ryder¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors;

¹City Hospital, Diabetes, Birmingham, UK

²Hull Royal Infirmary, Diabetes, Hull, UK

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, City Hospital, Birmingham, UK
²Diabetes, Hull Royal Infirmary, Hull, UK

Factors associated with HbA1c and weight changes at 6 months in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audit

C. Walton¹, R.E.J. Ryder², M.L. Cull², A.P. Mills², K.Y. Thong², ABCD nationwide exenatide and liraglutide audit contributors;

¹Diabetes, Hull Royal Infirmary, Hull, UK 
²Diabetes, City Hospital, Birmingham, UK

Safety and efficacy of using exenatide in combination with insulin in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit

B. Jose¹, R.E.J. Ryder¹, K.Y. Thong¹, S. Thozhukat², W. Shafiq², ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom, 
²Diabetes, Hull Royal Infirmary, Hull, United Kingdom

The Association of British Clinical Diabetologists (ABCD) nationwide exenatide and liraglutide audits

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton²,  ABCD nationwide exenatide and liraglutide audit contributors

¹Diabetes, City Hospital, Birmingham, UK

 ²Diabetes, Hull Royal Infirmary, Hull, UK

Problems with the NICE guideline for exenatide exposed in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit

R.E.J. Ryder¹, K.Y. Thong¹, M.L. Cull¹, A.P. Mills¹, C. Walton², K.A. Adamson³, D.S.Dove⁴ on behalf of the ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom

²Diabetes, Hull Royal Infirmary, Hull, United Kingdom

16.6% (1 in 6) patients who continued insulin at the time of exenatide start came off insulin in the Association of British Clinical Diabetologists (ABCD) Nationwide Exenatide Audit

K.Y. Thong¹, B. Jose¹, N. Sukumar¹, M.L. Cull¹, A. Mills¹, T. Sathyapalan², W. Shafiq², A. Rigby², C. Walton², R.E.J. Ryder¹, on behalf of the ABCD nationwide exenatide audit contributors

¹Diabetes, City Hospital, Birmingham, United Kingdom